Oral Insulin
Market size: Drug market for Type 2 diabetes estimated to reach $20 Billion in 2010*
- Unique in a competitive space -- Orally delivered, chemically unaltered human insulin
Established Safety and Efficacy Profiles
- Total human exposures > 500
- Two Type II patient studies presented at ADA 2003
- Potential first-line therapy for Type II diabetes
- Favorable kinetics consistently demonstrated
- Reproducible delivery from capsule and tablet dosage forms demonstrated
- EMISPHERE® delivery agent scale-up completed and inexpensive * source: Natexis Bleichroeder, “Diabetes is set for major innovation”, 9/03